
Wave Life Sciences ( ($WVE) ) has provided an update. On November 12, 2026, Wave Life Sciences held its annual meeting, where a quorum representing 84% of eligible shares was
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| WVE | Wave Life Sciences | 2.72 | -4.04 | -59.73% |
| Name | Price | % Change | |
|---|---|---|---|
| $2.72 | -59.73% |

Wave Life Sciences ( ($WVE) ) has provided an update. On November 12, 2026, Wave Life Sciences held its annual meeting, where a quorum representing 84% of eligible shares was

Wave Life Sciences Pte. Ltd (($WVE)) has held its Q3 earnings call. Read on for the main highlights of the call. Wave Life Sciences delivered a strongly positive earnings call,

Citi lowered the firm’s price target on Wave Life Sciences (WVE) to $15 from $19 and keeps a Buy rating on the shares. The firm updated the company’s model post

B. Riley lowered the firm’s price target on Wave Life Sciences (WVE) to $18 from $22 and keeps a Buy rating on the shares. Data from the obesity combo and

In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Wave Life Sciences, with a price target of $44.00. Whitney Ijem’s rating is based on

Analyst Yun Zhong of Wedbush maintained a Buy rating on Wave Life Sciences, retaining the price target of $12.00. Yun Zhong’s rating is based on several factors, including WVE-008’s potentially

BofA analyst Alec Stranahan lowered the firm’s price target on Wave Life Sciences (WVE) to $16 from $17 and keeps a Buy rating on the shares. Published first on TheFly

Canaccord analyst Whitney Ijem raised the firm’s price target on Wave Life Sciences (WVE) to $44 from $42 and keeps a Buy rating on the shares. The firm said they

After Wave Life Sciences (WVE) reported Q3 revenue and losses, H.C. Wainwright analyst Andrew Fein issued thoughts on WVE-006 and WVE-007 and argued that shares remain “undervalued into a catalyst-rich

Oppenheimer analyst Cheng Li lowered the firm’s price target on Wave Life Sciences (WVE) to $29 from $32 and keeps an Outperform rating on the shares after the company reported
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 17, 2026 | ||||
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| buy | Assigned | Oct 29, 2026 | ||||
| buy | Assigned | Oct 28, 2026 | ||||
| buy | Reiterated | Oct 28, 2026 | ||||
| buy | Reiterated | Oct 28, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 4, 2027TBA | $546.32M | $-0.32 | $10.43M | -0.19 | -2.59 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.